` COR (Cencora Inc) vs S&P 500 Comparison - Alpha Spread

COR
vs
S&P 500

Over the past 12 months, COR has outperformed S&P 500, delivering a return of +30% compared to the S&P 500's +16% growth.

Stocks Performance
COR vs S&P 500

Loading
COR
S&P 500
Add Stock
www.alphaspread.com

Performance Gap
COR vs S&P 500

Loading
COR
S&P 500
Difference
www.alphaspread.com

Performance By Year
COR vs S&P 500

Loading
COR
S&P 500
Add Stock

Competitors Performance
Cencora Inc vs Peers

Cencora Inc
Glance View

Cencora Inc., once known as AmerisourceBergen, stands as a pivotal player in the healthcare landscape, sculpting pathways for the seamless distribution of pharmaceuticals across the globe. Born from a merger of AmeriSource Health Corporation and Bergen Brunswig Corporation in 2001, the company carved its identity by building extensive networks that bind drug manufacturers, pharmacies, and healthcare providers together into a cohesive chain. This intricate web ensures that pharmaceutical products, ranging from common prescriptions to specialized drugs, reach their destinations efficiently and securely. Cencora's proficiency lies not just in logistics but in its ability to adapt and innovate within rigid regulatory frameworks, ensuring its clients navigate the complexities of compliance while focusing on patient care. In terms of profitability, Cencora thrives on its vast and exponentially growing distribution channels, earning a steady stream of revenue through service fees and percentage fees tied to the value of distributed goods. Moreover, the company's integrated service offerings, such as consulting, analytics, and supply chain management solutions, provide additional avenues of income by addressing the strategic needs of its clientele. This dual approach of logistics and consultancy allows Cencora not only to serve as a conduit for drug distribution but also as a trusted advisor in a healthcare sphere that is increasingly data-driven and efficiency-focused. Through its multi-faceted business model, Cencora secures its foundation in a volatile industry, supporting the balance of patient needs, market demands, and regulatory compliance.

COR Intrinsic Value
492.27 USD
Undervaluation 40%
Intrinsic Value
Price
Back to Top